Last reviewed · How we verify
Oral antacid
At a glance
| Generic name | Oral antacid |
|---|---|
| Also known as | Antacid, Mi-Acid Maximum Strength Liquid, Maalox, Aluminum hydroxide and magnesium hydroxide, Isentress, Maalox Plus Extra Strength |
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults (PHASE1)
- A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) (PHASE1)
- Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection (PHASE2)
- Optimizing PTCy Dose and Timing (PHASE1, PHASE2)
- Risk of Anemia and Effects of Oral Iron Therapy in Non-Anemic Iron-Deficient Women (18-55 Years) (NA)
- Clinical Evaluation of the Effectiveness of Biomimetic Hemostatic Sponges ColiSorB Following Dental Extraction (EARLY_PHASE1)
- Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy (PHASE3)
- Famotidine and Antacids for Treatment of Dyspepsia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral antacid CI brief — competitive landscape report
- Oral antacid updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI